证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-073 黑龙江珍宝岛药业股份有限公司 关于控股股东部分股份质押延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●黑龙江珍宝岛药业股份有限公司（以下简称"公司"）控股股东黑龙江创 达集团有限公司（以下简称"创达集团"）因可交换公司债券换股，截至 2025 年 10 月 10 日持有公司股份 560,710,023 股无限售流通股，占公司总股本的 59.59%，创达集团未间接持有公司股份，无一致行动人。 一、股份质押延期情况 （一）本次股份质押延期情况 创达集团于 2021 年 10 月 28 日质押给哈尔滨农村商业银行股份有限公司（以 下简称"哈农商行"）6,750 万股公司股份，质押期限自 2021 年 10 月 27 日至 2025 年 10 月 13 日（具体内容详见公司于 2021 年 10 月 29 日和 2024 年 10 月 17 日在 上交所网站 www.sse.com.cn 披露的临 2021-036 号和临 2024 ...

Group 1 - The Chinese medicine concept continues to rise, with Wanbangde hitting the daily limit, and companies such as Kangzhi Pharmaceutical, Tianmu Pharmaceutical, Zhenbaodao, and Jilin Aodong also experiencing gains [1]

Core Viewpoint - The Chinese medicine sector experienced a slight increase of 0.51% on October 9, with Zhenbaodao leading the gains. The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1]. Group 1: Stock Performance - Zhenbaodao (603567) closed at 11.60, with a rise of 4.50% and a trading volume of 135,100 shares, amounting to a transaction value of 156 million yuan [1]. - Mayinglong (600993) closed at 27.01, increasing by 2.12% with a trading volume of 79,600 shares, resulting in a transaction value of 214 million yuan [1]. - Yiling Pharmaceutical (002603) closed at 16.20, up 1.95% with a trading volume of 166,000 shares, totaling 267 million yuan in transaction value [1]. - Wanbangde (002082) closed at 12.21, rising by 1.83% with a trading volume of 314,300 shares, leading to a transaction value of 380 million yuan [1]. - Qidi Pharmaceutical (000590) closed at 11.69, increasing by 1.83% with a trading volume of 57,800 shares, amounting to 66.27 million yuan [1]. Group 2: Capital Flow - The Chinese medicine sector saw a net outflow of 247 million yuan from institutional investors, while retail investors contributed a net inflow of 134 million yuan [2]. - The main capital inflow was observed in Jilin Aodong (000623) with a net inflow of 30.13 million yuan, representing 6.33% of the total [3]. - Mayinglong (600993) experienced a net inflow of 23.70 million yuan from main capital, accounting for 11.10% [3]. - Renhe Pharmaceutical (000650) had a net inflow of 23.10 million yuan, making up 13.72% of the total [3]. - Wanbangde (002082) saw a net inflow of 17.28 million yuan from main capital, which is 4.54% [3].

Core Points - The Shanghai Composite Index is currently at 3913.21 points, above the annual line, with a change of 0.78% [1] - The total trading volume of A-shares today is 1,302.057 billion yuan [1] - A total of 55 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1] Summary of Key Stocks - Tianli Composite (证券代: 920576) has a price increase of 12.86% and a deviation rate of 11.43% [1] - China General Nuclear Power Technology (证券代: 000881) has a price increase of 6.55% and a deviation rate of 5.45% [1] - Baoland (证券代: 688058) has a price increase of 6.14% and a deviation rate of 4.86% [1] - Other stocks with notable performance include Chenguang Medical (证券代: 920300) with a 5.57% increase and a 2.94% deviation rate, and Sunlight Energy (证券代: 000591) with a 3.08% increase and a 2.71% deviation rate [1] Additional Stocks with Minor Deviations - Stocks like Xiamen International Trade (证券代: 000155) and Guizhou Wheel Tire (证券代: 000589) have minor deviations of 1.14% and 0.96% respectively, indicating they have just crossed the annual line [2]

Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on October 28, 1996, and listed on April 24, 2015. The company focuses on the research, production, and sales of high-end traditional Chinese medicine formulations, with a diverse range of dosage forms and products [2]. Financial Performance - For the first half of 2025, Zhenbaodao reported operating revenue of 714 million yuan, a year-on-year decrease of 57.05%. The net profit attributable to the parent company was -78.29 million yuan, reflecting a year-on-year decline of 119.90% [2]. - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Zhenbaodao's stock price decreased by 2.09%, trading at 11.27 yuan per share, with a total market capitalization of 10.605 billion yuan. The stock has seen a decline of 1.57% year-to-date, 8.74% over the last five trading days, 11.05% over the last 20 days, and 3.18% over the last 60 days [1][2]. - The trading volume on September 23 was 17.7324 million yuan, with a turnover rate of 0.17%. The net inflow of main funds was 1.9645 million yuan, with significant buying activity from large orders [1]. Business Segmentation - The main business revenue composition includes: 84.82% from the sale of proprietary Chinese medicines, 7.13% from purchased medicinal materials, 5.11% from purchased pharmaceuticals, 2.51% from other sources, 0.35% from rental income, and 0.07% from interest income [2]. - Zhenbaodao is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]. Shareholder Information - As of July 18, the number of shareholders for Zhenbaodao was 21,500, an increase of 2.34% from the previous period. The average circulating shares per person decreased by 2.29% to 43,744 shares [2].

Core Insights - The traditional Chinese medicinal materials trading industry faces challenges such as fragmentation, lack of standardization, and modernization, leading to issues like price discrepancies and quality inconsistencies, which affect medication safety and industry reputation [1] - The Bozhou Chinese Medicinal Materials Commodity Trading Center is launching an upgraded "Bulk Chinese Medicinal Materials Trading Platform" during the 2025 International (Bozhou) Pharmaceutical Expo, aiming to reshape the industry ecosystem with innovative mechanisms [1][2] Industry Development - Recent government policies, including the "14th Five-Year Plan for Traditional Chinese Medicine Development," are promoting the standardization and high-quality development of the Chinese medicinal materials industry [2] - Bozhou, as the largest distribution center for Chinese medicinal materials in China, is undergoing a transformation that has garnered significant industry attention [2] Trading Platform Innovations - The new trading platform introduces a warehouse receipt trading model, enhancing the standardization and efficiency of transactions while addressing traditional pain points such as low efficiency and high costs [2][3] - The platform's full online process and electronic warehouse receipt system aim to improve transparency and reduce costs in the supply chain [2][3] Mechanisms Addressing Industry Pain Points - The platform focuses on online, standardized, and financialized trading to tackle issues like price chaos, quality concerns, high costs, and financing difficulties [3] - Financial support services such as accounts receivable financing and order financing are designed to alleviate cash flow issues for small and medium-sized businesses [3] - Collaboration with local governments to implement GAP certification and traceability systems aims to enhance quality control and reduce overall costs in the supply chain [3] Innovative Trading Mechanism - The "spot + warehouse receipt" trading mechanism allows for standardized storage and multiple circulations of medicinal materials, significantly lowering transaction costs and improving efficiency [4] - The platform anticipates achieving transaction volumes of at least 300 million yuan in 2025, 3 billion yuan in 2026, and over 10 billion yuan in 2027, with a long-term goal of exceeding 100 billion yuan in annual transactions within five years [4] Strategic Integration - The trading platform serves as a strategic initiative for Zhenbaodao Pharmaceutical to enhance supply chain control, stabilize product quality, and reduce cost fluctuations [5] - By integrating high-quality resource areas and establishing a traceable raw material supply system, the company aims to improve procurement negotiation capabilities and inventory management flexibility [5] - The platform is positioned as a key strategy for Zhenbaodao Pharmaceutical to innovate traditional trading methods and tap into supply chain finance, potentially creating significant growth opportunities in the traditional Chinese medicine sector [5]

Core Viewpoint - The report outlines a reduction in the shareholding of Heilongjiang Chuangda Group Co., Ltd. in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the conversion of exchangeable bonds, resulting in a decrease in ownership from 60.85% to 59.87% [19][21]. Group 1: Shareholding Changes - The shareholding of Heilongjiang Chuangda Group decreased by 0.98% due to the conversion of 9,223,963 shares from the exchangeable bonds "23 Chuang 01 EB" and "23 Chuang 02 EB" [5][21]. - As of the report date, Heilongjiang Chuangda Group holds 563,334,314 shares, representing 59.87% of the total share capital of the company [19][21]. - The total shares converted from both exchangeable bonds amount to 16,550,986 shares, accounting for 1.76% of the total share capital [21]. Group 2: Future Plans and Compliance - Heilongjiang Chuangda Group has no plans to increase or decrease its shareholding in the next 12 months, aside from the ongoing conversion of the exchangeable bonds [4][21]. - The report confirms that the shareholding change does not trigger a mandatory tender offer and will not alter the status of the controlling shareholder or actual controller [19][22]. - The company has complied with all relevant laws and regulations regarding the disclosure of this shareholding change [22].

黑龙江珍宝岛药业股份有限公司 简式权益变动报告书 上市公司名称:黑龙江珍宝岛药业股份有限公司 股票上市地点:上海证券交易所 股票简称：珍宝岛 股票代码：603567 信息披露义务人：黑龙江创达集团有限公司 住所/通讯地址：虎林市解放西街北检察院东侧宝润香林里1号楼1号门市 股份变动性质：股份减少 签署日期：2025年9月18日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 五、信息披露义务人保证本报告书及相关文件内容的真实性、准确性、完整性， 承诺其中不存在虚假记载、误导性陈述或重大遗漏，并就其保证承诺承担个别和连 带的法律责任。 1 | | | 释义 在本报告书中，除非另有说明，下列词语具有如下特定含义： | 公司、上市公司、珍宝岛 | 指 | 黑龙江珍宝岛药业股份有限公司 | | --- | --- | --- | | 信息披露义务人、创达集团 | 指 | 黑龙江创达集团有限公司 | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动后，黑龙江创达集团有限公司（以下简称"创达集团"）持有黑 龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）股份 563,334,314 股，占公司总股本的 59.87%。 本次权益变动属于创达集团发行的可交换公司债券持有人换股造成权益变动 人被动减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 一、本次权益变动基本情况 公司于近日收到控股股东创达集团的《简式权益变动报告书》，获悉创达集团发 行的 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交换债券"）和 2023 年面向专业投资者非公开发行可交换公司债券（第二期） （以下简称"第二期可交换债券"）的债券持有人发生换股，导致创达集团持股比例 被动下降，持有公司股份比例从 60.85%减少至 59.87%，跨越了 60%的刻度，现将本 次权益变动相关事项公告如下： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-072 黑龙 ...

Core Points - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. announced a notice regarding changes in the equity of its controlling shareholder [1] - From August 2 to September 18, the controlling shareholder, Chuangda Group, exchanged two tranches of convertible bonds for 9,223,963 shares, accounting for 0.98% of the total share capital [1] - As of September 18, a total of 16,550,986 shares have been exchanged, representing 1.76% of the total share capital [1] - Following this equity change, Chuangda Group's shareholding ratio decreased from 60.85% to 59.87%, crossing below the 60% threshold [1] - This change is a result of bondholders exercising their conversion rights, leading to a passive reduction in holdings, and does not trigger a mandatory tender offer or change the company's controlling shareholder or actual controller [1] - The company will continue to monitor the share conversion and disclose information in accordance with regulations, reminding investors to pay attention to risks [1]